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AcetylcholineThe induction of nitric oxide synthase (iNOS) expression via the signal transducer and activator of transcription 1
(STAT-1) is involved in the mechanism of oxidative/nitrosative stress. We investigated whether acetylcholine
(ACh) generates oxidative/nitrosative stress in bronchial epithelial cells during airway inﬂammation of COPD
and evaluated the effects of Tiotropium, a once-daily antimuscarinic drug, and Olodaterol, a long-acting
β2-agonist on these mechanisms. Human bronchial epithelial cells (16-HBE) were stimulated (4 h, 37 °C)
with induced sputum supernatants (ISSs) from healthy controls (HC) (n = 10), healthy smokers (HS) (n = 10)
or COPD patients (n = 10), as well as with ACh (from 1 μM to 100 μM). The activation of STAT-1 pathway
(STAT-1Ser727 and STAT-1Tyr701) and iNOS was evaluated in the cell lysates by Western blot analysis as well
as nitrotyrosine levels by ELISA, while reactive oxygen species (ROS) were evaluated by ﬂow cytometry. Finally,
the effect of Tiotropium (Spiriva®) (100 nM), alone or in combinationwith Olodaterol (1 nM),was tested in this
model. ISSs from COPD patients signiﬁcantly increased the phosphorylation of STAT-1Ser727 and STAT-1Tyr701,
iNOS and ROS/Nitrotyrosine when compared with ISSs from HC or HS subjects in 16-HBE cells. Furthermore,
synthetic ACh increased all these parameters in stimulated 16HBE when compared with untreated cells.
Tiotropium and Olodaterol reduced the oxidative/nitrosative stress generated by ACh and ISSs. We concluded
that ACh mediated the oxidative/nitrosative stress involving the STAT-1 pathway activation in human bronchial
epithelial cells during COPD. β2-Long acting and antimuscarinic drugs, normally used in the treatment of COPD
as bronchodilator, might be able to control these cellular events.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Oxidative stress, deﬁned as an increase in oxidants and/or a decrease
in antioxidant capacity, is associated with inﬂammatory airway dis-
eases, including asthma and Chronic Obstructive Pulmonary Disease
(COPD). Airway cells, especially eosinophils and epithelial cells, under
inﬂammatory conditions, produce more superoxide anions (O2−) and
release reactive nitrogen compounds (NO) and reactive oxygen species
(ROS) than normal airway cells [1]. NO and O2− react producing
peroxynitrite anions promoting the nitrosylation of tyrosine residue ofMolecular Immunology, Italian
90146 Palermo, Italy. Tel.: +39
rights reserved.proteins to form nitrotyrosine in the airway of asthma and COPD pa-
tients [2]. Recent studies showed a strong immunoreactivity to
Nitrotyrosine in the epithelium, lung parenchyma, and inﬂammatory
cells (eosinophils, neutrophils) in patients with inﬂammatory airway
diseases such as COPD [3]. Nitrotyrosine and ROS production often co-
exists within the cells [4].
The inducible nitric oxide synthase (iNOS) expression plays a
prominent role in the mechanism of oxidative/nitrosative stress of
various cell types [5]. Among signaling pathways implicated in con-
trolling the activation of iNOS transcription factors and subsequent
iNOS expression, NF-κB pathway, mitogen-activated protein kinases
(MAPK), and Janus kinase (JAK)/STAT-dependent signal transduction
appear to have a relevant role [6,7].
Acetylcholine (ACh) is synthesized by choline acetyltransferase
(ChAT) in different cell types such as macrophages, T lymphocytes,
ﬁbroblasts and epithelial cells [8]. Recent ﬁndings described ACh as
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processes in COPD, targeting the cells via muscarinic acetylcholine
receptors (mAChRs) [9–11]. Further, we have shown that ACh was
increased in induced sputum supernatants from COPD patients com-
pared with healthy controls [12]. ACh affects ROS production by
activation of Phosphoinositide 3-kinase (PI3K), Src-kinases or the
extracellular signal-regulated kinase (ERK) pathway in adult rabbit
ventricular myocytes [13] suggesting its involvement in the mecha-
nism of oxidative stress in the cells.
The current guidelines recommend the regular use of β2-AR-
agonists and anticholinergics alone or as concurrent therapy in
COPD to maximize bronchodilation [14,15]. It was demonstrated
that Tiotropium is able to counteract the proinﬂammatory activity
of ACh on different cell types [10,16–19] and is involved in the control
of oxidative stress regulating “ex vivo” the release of ROS in peripher-
al blood neutrophils from COPD subjects [20]. Further recent ﬁndings
showed that β2-AR-agonists and antimuscarinic additively control
TGF-β1-mediated neutrophilic inﬂammation in COPD [12]. However,
the antioxidant efﬁcacy of this combination is not yet widely studied.
Since the oxidative/nitrosative stress and ACh are implicated in
the activation of bronchial epithelial cells in COPD, in this study we
aimed to investigate whether ACh is able to generate oxidative/
nitrosative stress during airway inﬂammation. Finally, we evaluated
the effects of the once-daily anticholinergic Tiotropium and the
long-acting β2-agonist Olodaterol, alone or in combination, on the
cellular oxidative and nitrosative activities of ACh.
2. Materials and methods
2.1. Subjects
We included three groups of subjects: healthy non-smoking sub-
jects (HC) (n = 10), asymptomatic smokers with normal lung function
(HS) (n = 10), and patients with COPD (n = 10). COPD was deﬁned
and classiﬁed according to the criteria reported by Global Initiative for
Chronic Obstructive Lung Disease (GOLD) guidelines as stage ≥1 [21].
Reversibility test to bronchodilator was performed to exclude an
asthmatic component, and the increase in forced expiratory volume
in the 1st second (FEV1) after salbutamol was lower than 12% and
200 ml compared with basal values, in all COPD subjects. All COPD pa-
tients were in stable conditions. COPD patients who had routine chest
X-rays and computed tomographic scans that showed emphysema
were excluded.
Patients selected for induced sputum (IS) collection underwent an
initial 2-week run-in period. All patients were characterized with re-
spect to gender, age, smoking history, COPD symptoms, comorbidity,
and current history of treatment (Table 1). Exclusion criteria included
the following: other systemic diseases, chronic bronchitis, chronic
spontaneous, sputum production, other lung diseases, upper and
lower respiratory tract infections, treatment with glucocorticoids orTable 1
Demographic characteristics of patients.
HC HS
Age, yr 63 ± 7 60.5 ± 7
Gender, male/female 5/5 6/4
FEV1, % predicted 111.6 ± 10.6 103.2 ± 10
FVC, % predicted 108.4 ± 16.2 107.1 ± 15
FEV1 post β2 (% from baseline) – –
FEV1/FVC (%) 94.6 ± 3.0 89.3 ± 4.9
FEV1/FVC post β2 (% from baseline) – –
Smoking, pack/yr 0 62.5 ± 17.0
Data are presented as mean ± SD. Abbreviations: HC = asymptomatic nonsmoking subject
COPD = subject with Chronic Obstructive Pulmonary Disease; FEV1 = forced expiratory
comparisons was calculated using Kruskal–Wallis and nonparametric ANOVA tests followeantimuscarinics within 3 months before the study and treatment
with long acting β2-adrenergic agonists 15 days before the study.
The local Ethics Committee approved the study, and participating
subjects gave their informed consent.
2.2. Pulmonary function tests
Pulmonary function tests included measurements of FEV1, FVC,
and PEF. The reversibility of the airway obstruction in subjects with
a baseline FEV1% is less than 80% of predicted. To assess the revers-
ibility, the FEV1 measurement was repeated 15 min after the inhala-
tion of 200 μg of salbutamol. Data are expressed as percentage of
predicted values.
2.3. Sputum induction and processing
Sputum induction and processing were performed with the plug
method as previously described [10] according to the methods of
Hargreave et al. [22]. The volume of the induced sputum was previ-
ously determined, and an equal volume of Dithiothreitol (DTT)
(0.1% in saline; Sigma, St. Louis, MO) was added. After homogeniza-
tion, sputum samples were centrifuged at 800 g for 10 min to sepa-
rate the supernatants from the cell pellet. The supernatants were
then aspirated and frozen at −20 °C in separate aliquots. The cells
obtained from induced sputum were then cytocentrifuged (Cytospin
2; Shandon, Runcorn, United Kingdom) and stained with May–
Grunwald–Giemsa. Cytospins were used for differential cell counts.
2.4. Human bronchial epithelial cell culture
The SV40 large T antigen-transformed 16-HBE cell line (16-HBE)
was used for these studies. Evidences showed that 16-HBE are similar
to primary normal human bronchial epithelial (NHBE) cells (Lonza,
Brussels, Belgium), and bronchial epithelial cells (BECs) from bron-
chial brushings [23]. The cells represent a clonal diploid (2n = 6)
cell line isolated from human lung previously used to study the func-
tional properties of bronchial epithelial cells in inﬂammation and
repair processes. 16-HBE cells were cultured as adherent monolayers
in Eagle's minimum essential medium (MEM) supplemented with
10% heat-inactivated (56 °C, 30 min) fetal bovine serum (FBS), 1%
MEM (non-essential aminoacids, Euroclone), 2 mM L-glutamine and
gentamicin 250 μg/ml at 37 °C in a humidiﬁed 5% CO2 atmosphere.
2.5. Human bronchial epithelial cell stimulation with ACh
16-HBE were plated until conﬂuence withMEM 10% FBS (5% CO2 at
37 °C); after 24 h under FBS-free conditions, 16-HBE were stimulated
with various concentrations of ACh (from 1 μM to 100 μM) (Sigma St.
Louis, MO) for 4 h to evaluate the production of ROS and Nitrotyrosine.
The iNOS expression was evaluated in 16-HBE stimulated with AChCOPD p Value
HC vs HS HC vs COPD HS vs COPD
64 ± 13 ns ns ns
3/7 – – –
60.7 ± 55 ns b0.005 b0.02
70.6 ± 112 ns b0.03 b0.03
4 ± 2 – – –
64.4 ± 9.0 ns b0.001 b0.01
6 ± 2 – – –
62 ± 21.0 b0.002 b0.002 ns
s with normal lung function; HS = asymptomatic smokers with normal lung function;
volume in one second; FVC = forced vital capacity. Statistical analysis for multiple
d by Bonferroni Dunn correction.
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ACh 10 μM for 15 and 30 min at 37 °C to study the STAT-1 pathway
activation. To determine the involvement of the mAChRs on oxidative/
nitrosative stress generated in 16-HBE by ACh, Tiotropium (100 nM)
(Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany)
was added to 16-HBE 1 h before the stimulation with ACh 10 μM.
2.6. Human bronchial epithelial cell stimulation with ISSs
16-HBE (70,000 cells/well) were plated in standard 6-well culture
plates in MEM 10% FCS and grown to conﬂuence. After 24 h with
MEM 1% FCS, the medium was replaced and 16-HBE cells were stim-
ulated with ISSs (10% in fresh MEM 1% FCS) from COPD (n = 10)
patients, HS (n = 10) and HC (n = 10) subjects for 4 h at 37 °C to
evaluate ROS, Nitrotyrosine and iNOS production and for 30 min to
evaluate the STAT-1 pathway activation. 16HBE were stimulated
with DTT (0.1% in saline solution) to exclude the nonspeciﬁc effect
of DTT present in ISSs used in the experiments on iNOS, ROS, NT pro-
duction and on STAT-1 pathway activation.
Tiotropium Spiriva® (100 nM) (Boehringer Ingelheim Pharma
GmbH&Co. KG, Biberach, Germany) andOlodaterol (1 nM) (Boehringer
Ingelheim Pharma GmbH & Co. KG, Biberach, Germany) were added,
alone or in combination, to 16-HBE 1 h before the stimulation with
ISSs from 8 COPD patients.
Hemicholinium-3 (HCh-3) (50 μM, Sigma–Aldrich), a potent and
selective choline uptake blocker was added to the 16-HBE 1 h before
the stimulation with ISSs from COPD patients. After the stimulation,
the cells were recovered and analyzed for ROS, Nitrotyrosine, iNOS
and STAT-1 pathway activation. Cell viability was conﬁrmed by light
microscopy and trypan blue exclusion.
2.7. Detection of intracellular ROS
16-HBE cells, stimulated via the above methods, were detached by
trypsin, washed in PBS and collected in FACS tubes. Cells were then
incubated with the oxidant-sensitive dye 2′,7′-dichloroﬂuorescein
diacetate (DCFH-DA, 1 mM) in PBS for 10 min in the dark at room
temperature. After washing, cells were resuspended in PBS and then
analyzed by ﬂow cytometry for ﬂuorescence-positive cells. The intra-
cellular ROS generation was evaluated by ﬂow cytometry analysis
using a FACSCalibur™ ﬂow cytometer (Becton Dickinson, Mountain
View, CA, USA). Negative controls consisted of 16-HBE cells cultured
without DCFH-DA. Gating on the cells, excluding debris, was performed
using forward and sideways scatter patterns.
2.8. Nitrotyrosine detection
Nitrotyrosine levels were assessed in duplicate in cell lysates,
using the Nitrotyrosine ELISA kit purchased by Hycult Biotechnology
b.v. (HK-501, Uden, the Netherlands) according to the manufacturer's
instructions. Absorbance was read at 450 nm by a Wallac 1420 Victor2
multilabel counter (Perkin–Elmer Life Sciences, Turku, Finland). The
minimum detection level was 0.5 nM. We run as positive control
16-HBE protein extract nitrated with tetranitromethane (dissolved in
methanol) (4% v/v) (TNM) (Sigma–Aldrich, Italy) for 2 h and as nega-
tive control 16-HBE protein extract or bovine serum albumin (BSA,
1 mg/ml) (Sigma–Aldrich, Italy).
2.9. RNA interference of the STAT-1 pathway
To conﬁrm that the increase of iNOS, ROS and Nitrotyrosine produc-
tion is associated with ACh or with ISSs dependent STAT-1 activation,
we tested the effect of p91/STAT-1 silencing in human bronchial epithe-
lial cells using a speciﬁc siRNA transfection [24]. 16-HBE cells were
plated in six well tissue culture plates and grown inmedium containing
10% FBS without antibiotics until 60 to 80% conﬂuency. p91/STAT-1αsiRNA (10 μM; Santa Cruz Biotechnology, Inc.) was then added to
100 μl of siRNA transfection medium, and the reaction was performed
according to the manufacturer's instructions until complete cell trans-
fection (7 h at 37 °C). For optimal siRNA transfection efﬁciency, siRNA
(10 μM; Santa Cruz Biotechnology, Inc.) containing a scrambled
sequence that did not lead to the speciﬁc degradation of any known
cellular mRNA was used to control non-speciﬁc effects. Finally, cells
were stimulatedwith ISSs fromCOPDorACh10 μMfor 4 h. The silencing
efﬁcacy of RNA interference in p91/STAT-1α was assessed by Western
blot analysis.
2.10. Western blotting
Total proteins were extracted from stimulated 16HBE cells using a
lysis buffer (NaCl 50 mM, Tris–HCl 10 mM, EDTA 5 mM, NP-40 1%)
containing a protease and phosphatase inhibitor. Protein concentration
was assessed using the Bradford method. The total protein extracts
were separated by SDS-PAGE on 10% gradient gels followed by
electroblottingonto nitrocellulosemembranes. The followingantibodies
were used: rabbit polyclonal anti-phospho-STAT1 (Ser727 and Y710)
(Upstate Biotechnology, Temecula CA), rabbit polyclonal anti-STAT-
1α/p91 (C-24) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and
rabbit polyclonal anti-iNOS (Abcam, Cambridge, UK). β-Actin (Sigma-
Aldrich)was used as a housekeeping protein to control the total amount
of protein in each sample. Cell extracts were transferred to micro-
centrifuge tubes, left on ice for 45 min, and centrifuged at 15,000 g for
20 min at 4 °C. Forty micrograms of protein was subjected to
SDS-polyacrylamide gel electrophoresis on 8 to 10% gradient gels and
blotted onto nitrocellulose membranes. After blocking with PBS
containing 5% milk and 0.1% Tween 20, membranes were probed
with speciﬁc antibodies, washed, and incubated with peroxidase-
conjugated secondary antibodies. Detection was performed with an
enhanced chemiluminescence system (Ambion, Austin, TX) followed
by autoradiography. Gel images were acquired using an Epson
GT-6000 scanner (Epson America, Torrance, CA) and then imported
into the National Institutes of Health Image analysis 1.61 program
to determine band intensity. Data are expressed as arbitrary densito-
metric units corrected against the density of β-actin bands.
2.11. Statistical analysis
Statistical analysis was calculated using Kruskal Wallis followed by
Bonferroni Dunn correction for multiple comparisons. Nonparametric
Kruskal Wallis test was chosen to verify that the population means
are equal. ANOVA with Fisher test correction was used for the analysis
of the data obtained from in vitro experiments. A p value b 0.05 was
considered as statistically signiﬁcant.
3. Results
3.1. Demographic characteristic of patients and differential cell counts of
ISS
The patients' characteristics are summarized in Table 1. The differ-
ential cell counts of induced sputum samples showed a signiﬁcant
increase of the cell number in COPD. In COPD and HS the percentage
of macrophages was signiﬁcantly lower and the percentage of neutro-
phils was signiﬁcantly higher than in HC. The percentage of lym-
phocytes, eosinophils, and epithelial cells did not show signiﬁcant
differences among the three study groups (Table 2).
3.2. ACh and ISSs increased the levels of oxidative/nitrosative stress in
human bronchial epithelial cells
ACh activated the oxidative and nitrosative stress in 16-HBE cells
promoting ROS and Nitrotyrosine production in a concentration-
Table 2
Total and differential cell count from induced sputum.
HC HS COPD p Value
HC vs HS HC vs COPD HS vs COPD
Macrophages (%) 83.2 (67.9–88.4) 52.6 (42.1–69) 20.6 (10.0–58.2) b0.02 b0.002 ns
Neutrophils (%) 18.3 (10–28.1) 45.0 (30.2–45.2) 72.0 (42.2–83.5) b0.02 b0.002 ns
Lymphocytes (%) 0.3 (0–1.2) 0.6 (0.4–1.3) 1.3 (0–1.5) ns ns ns
Eosinophils (%) 0.1 (0–0.7) 0.8 (0–1.4) 0.9 (0.2–2.4) ns ns ns
Epithelial cells (%) 0.6 (0.5–2.0) 0.7 (0–0.9) 0.6 (0–1.8) ns ns ns
Total cells (106/g ISS) 3.5 (2.1–7.8) 3.3 (3.5–6) 5.6 (3–14.8) ns ns ns
Results are expressed as median (25th to 75th percentiles) Statistical analysis for multiple comparisons was calculated using Kruskal–Wallis and nonparametric ANOVA tests
followed by Bonferroni Dunn correction. Abbreviations: HC = healthy asymptomatic nonsmoking subjects with normal lung function; HS = asymptomatic smokers with normal
lung function; COPD = subjects with Chronic Obstructive Pulmonary Disease; ns = not signiﬁcant.
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10 μM (Fig. 1, A) compared to untreated cells. Tiotropium 100 nM
reduced both ROS and Nitrotyrosine levels generated by ACh stimula-
tion (Fig. 1, B).
ISSs from COPD patients and from HS subjects increased ROS and
Nitrotyrosine production in stimulated 16-HBE cells when compared
to untreated cells and to the cells stimulated with ISSs fromHC subjects
(Fig. 2, A). The pretreatment of the cells with Tiotropium 100 nM
reduced the levels of both ROS and Nitrotyrosine production in
16-HBE cells stimulated with ISSs from COPD patients. Furthermore,
the pretreatment of the cells with Olodaterol (1 nM) reduced the levels
of ROS and Nitrotyrosine production in the cells. The pretreatment of
the cells with both Tiotropium and Olodaterol did not have an additive
or synergistic effect when the drugs were used in combination in the
experimental conditions (Fig. 2, B).Fig. 1. ACh activates the oxidative/nitrosative stress in 16-HBE cells. A) The 16-HBE were
(100 nM) was added to 16-HBE 1 h before the stimulation with ACh 10 μΜ for 4 h. At the en
rescent positive cells) by ﬂow cytometry and Nitrotyrosine (nM) in cell lysates by ELISA. The
as mean ± S.D. ANOVA with Fisher's test correction was used for the analysis of the data.3.3. ACh and ISSs increased the iNOS expression in human bronchial
epithelial cells
ACh increased the expression of iNOS in 16-HBE cells, in a time
dependent manner reaching the higher levels after 4 h of stimulation.
The iNOS control value for the longer stimulation period of 4 h of ACh
exposure, is nearly identical to the values obtained in the 2 h groups
but different from the other control value (Fig. 3, A). The pretreatment
of the cells with Tiotropium 100 nM reduced the levels of iNOS expres-
sion generated in 16-HBE cells stimulatedwith ACh 10 μMcompared to
untreated cells (Fig. 3, B).
ISSs from COPD patients signiﬁcantly increased the expression of
iNOS in 16-HBE cells, in comparison to untreated cells or stimulation
with ISSs from HC and HS subjects (Fig. 3, C). The pretreatment of
the cells with Tiotropium or Olodaterol reduced the levels of iNOSstimulated with different concentrations of ACh (0 to 100 μΜ) for 4 h; B) Tiotropium
d of the stimulation, we evaluated intracellular ROS production (as percentage of ﬂuo-
bars represent the data from six independent experiments. The results were expressed
Fig. 2. ISSs activate the oxidative/nitrosative stress in 16-HBE cells. A) The 16-HBE were stimulated with ISSs from COPD patients (n = 10) and from HS (n = 10) and HC (n = 10)
subjects for 4 h; B) Tiotropium (100 nM) and Olodaterol (1 nM) alone or in combination were added to 16-HBE 1 h before the stimulation with ISSs for 4 h. At the end of the stim-
ulation, ROS production was evaluated in the cells by ﬂow cytometry and Nitrotyrosine in cell lysates by ELISA. The results were expressed as mean ± S.D. ANOVA with Fisher's test
correction was used for the analysis of the data.
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patients. The pretreatment of the cells with both Tiotropium and
Olodaterol did not exert any additive or synergistic effects (Fig. 3, D).3.4. ACh and ISSs activated the STAT-1 pathway
ACh increased in 16-HBE cells the pSTAT-1 Tyr701 and pSTAT-1
Ser727 phosphorylation in a time-dependent manner, reaching higher
levels after 30 min of stimulation compared to untreated cells. The
pSTAT-1 Tyr701 and pSTAT-1 Ser727 phosphorylation control value
for the longer stimulation period of 30 min of ACh exposure, is nearly
identical to the values obtained in the 15 min groups but different
from the other control value (Fig. 4, A). The pretreatment with
Tiotropium reduced the levels of STAT-1 pathway phosphorylation
generated by ACh (Fig. 4, B).
ISSs from COPD patients activated the STAT-1 pathway in 16-HBE
cells, promoting increased levels of pSTAT-1 Tyr701 and pSTAT-1
Ser727 compared to untreated cells and to the cells stimulated with
ISSs from HC subjects. Further, ISSs from HS subjects increased in
16-HBE cells the level of pSTAT-1 Ser727 compared to untreated
cells and to the cells stimulated with ISSs from HC subjects (Fig. 5, A).
The pretreatment of 16-HBE with Tiotropium or Olodaterol reduced
the levels of pSTAT-1 Tyr701 and pSTAT-1 Ser727 generated by ISSs
from COPD patients. The pretreatment with Tiotropium and Olodaterol
in combination showed an additive effect in the reduction of STAT-1
pathway activation (Fig. 5, B). Finally, we observed that the stimulation
of 16HBE with DTT (0.1% saline solution) did not increase the pSTAT-1
Tyr701 and pSTAT-1 Ser727 when compared with untreated cells
(Fig. 5).
The HCh-3, a potent and selective choline uptake blocker, was able
to reduce the levels of pSTAT-1 Tyr701 and pSTAT-1 Ser727 (Fig. 6, A),
ROS (Fig. 6, B), Nitrotyrosine production (Fig. 6, C), and iNOS expression(Fig. 6, D) in untreated 16-HBE cells and in 16HBE stimulated with ISSs
from COPD patients. Finally, we observed that the stimulation of 16HBE
with DTT (0.1% saline solution) did not increase the ROS, iNOs and
Nitrotyrosine production when compared with untreated cells (Fig. 6).
3.5. Effect of STAT-1 silencing on ROS, NT and iNOS in 16-HBE cells
Temporary cell transfection with p91/STAT-1α siRNA signiﬁcantly
decreased the synthesis of STAT-1 protein and iNOs in 16-HBE. Further-
more, the temporary cell transfection with control siRNA (scrambled
sequence) was not different than untreated cells showing a speciﬁc ef-
fect of transfectionwith p91/STAT-1α siRNA (Fig. 7, A). The silencing of
p91/STAT-1α reduced the levels of iNOS, ROS andNitrotyrosineproduc-
tion (Fig. 7, B, C and D) in 16-HBE stimulatedwith synthetic ACh or ISSs
from COPD patients when compared with stimulated unsilenced
16-HBE. Furthermore, in a few number of experiments (n = 2) we
obtained that the response to ACh or ISSs from COPD patients was not
affected in the cells transfected with control siRNA when compared
with untreated cells (data not shown). Finally, we observed that the
stimulation of 16HBE with DTT (0.1% saline solution) did not increase
the ROS, and Nitrotyrosine production in silenced and unsilenced cells
when compared with untreated cells (Fig. 7, C, D).
These ﬁndings support the newly described role of STAT-1 activa-
tion in the transduction pathway leading to the enhanced oxidative/
nitrosative stress in 16-HBE cells.
4. Discussion
We studied oxidative/nitrosative stress markers, in terms of ROS
and Nitrotyrosine production, in an in vitro model of human bronchial
epithelial cells, in response to ACh or airway inﬂammation present in
induced sputum supernatants from COPD patients. We observed that
Fig. 3. ACh and ISSs activate the iNOS expression in 16-HBE cells. A) The 16-HBE were stimulated with ACh 10 μΜ for 2 and 4 h; B) Tiotropium (100 nM) was added to 16-HBE 1 h
before the stimulation with ACh 10 μΜ for 4 h. C) The 16-HBE were stimulated with ISSs from COPD patients (n = 10) and from HS (n = 10) and HC (n = 10) subjects for 4 h;
D) Tiotropium (100 nM) and Olodaterol (1 nM) alone or in combination were added to 16-HBE 1 h before the stimulation with ISSs from COPD patients for 4 h. At the end of stim-
ulation, the iNOS expression was evaluated in cell lysates by Western blot. The bars of A, B and D represent the densitometric analysis of iNOS from six independent experiments.
The bars of C represent the densitometric analysis of iNOS from ten independent experiments. Representative gel images of iNOS expression were shown. The results were
expressed as mean ± S.D. ANOVA with Fisher's test correction was used for the analysis of the data.
Fig. 4. ACh activates the STAT-1 pathway in 16-HBE cells. A) The 16-HBEwere stimulatedwith ACh 10 μΜ for 15 and 30 min; B) Tiotropium(100 nM)was added to 16-HBE1 h before the
stimulation with ACh 10 μΜ for 30 min. At the end of the stimulation the cell extracts were separated with 10% SDS-polyacrylamide gel electrophoresis, andWestern blot analyses were
carried out sequentially with anti-phosphoSTAT-1Ser727, anti-phosphoSTAT-1Tyr701, and anti-β-actin antibodies. Representative Western blot of anti-phosphoSTAT-1Ser727,
anti-phosphoSTAT-1Tyr701and relative β-actin are shown. The bars represent the densitometric analysis of six separate experiments. The results were expressed as mean ± S.D.
ANOVA with Fisher's test correction was used for the analysis of the data.
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Fig. 5. ISSs activate the STAT-1 pathway in 16-HBE cells. A) The 16-HBE cells were stimulated with ISSs from COPD patients (n = 10), HS (n = 10), HC (n = 10) subjects or DTT for
30 min. B) Tiotropium (100 nM) and Olodaterol (1 nM) alone or in combination were added to 16-HBE 1 h before the stimulation with ISSs for 30 min. At the end of the stimu-
lation the cell extracts were separated with 10% SDS-polyacrylamide gel electrophoresis, and Western blot analyses were carried out sequentially with anti-phosphoSTAT-1Ser727,
anti-phosphoSTAT-1Tyr701, and anti-β-actin antibodies. Representative Western blot of anti-phosphoSTAT-1Ser727, anti-phosphoSTAT-1Tyr701 and the relative β-actin are
shown. The bars of A represent the densitometric analysis of pSTAT-1Ser727, pSTAT-1Tyr701 from ten independent experiments. The bars of B represent the densitometric analysis
of pSTAT-1Ser727, pSTAT-1Tyr701 from six independent experiments. The results were expressed as mean ± S.D. ANOVA with Fisher's test correction was used for the analysis of
the data.
1955M. Proﬁta et al. / Biochimica et Biophysica Acta 1832 (2013) 1949–1958this pathological event may be associated with an increased expression
of iNOS due to STAT-1 downstream signaling activation. Finally in our in
vitro model, showing that Tiotropium or Olodaterol might be able to
control the oxidative and nitrosative stress markers generated in bron-
chial epithelial cells of inﬂammation, we support the concept of long
term beneﬁcial effects of β2-adrenoceptoragonists and muscarinic an-
tagonist treatment during airway inﬂammation.
Inﬂammation is considered of primary pathogenic importance in
COPD. The current therapeutic approach suggests the use of anticho-
linergic and long-acting β2 agonists in the treatment of COPD to
maximize bronchodilatation [14,15]. The utility of the treatment of
both, anti-inﬂammatory and bronchodilatatory drugs has relatively
recently been included in the current guidelines at least in certain
stages of the disease. Demonstrating that antimuscarinic drugs and
β2 long-acting might exert an anti-inﬂammatory or an antioxidant/
antinitrosative action, we suggest an additional long-term beneﬁcial
effect of these drugs in the treatment of COPD.
Various studies in myocytes emphasize the stimulating effect of
cholinergic stimulation on ROS production which is caused by activation
of PI3K, Src-kinases or the ERK pathway at least leading to the opening
of mitochondrial KATP channels and ROS release [25,26]. ROS by them-
selves trigger chemokine production in inﬂammatory cells thus enhanc-
ing the inﬂammatory process [26,27]. The involvement of the cholinergic
system in ROS and ROS-mediated cytotoxicity, makes it an ideal system
to test muscarinic receptor inhibitors for their cell protective function
[28]. Today, more than one ﬁnding describe the immunomodulatory
effects of ACh, potentially inﬂuencing the inﬂammatory processes in
COPD [10,11,18,19]. In accordance with these observations, we showed
that “in vitro” synthetic ACh is able to increase the ROS production andthe antimuscarinic Tiotropium is able to inhibit this effect in 16 HBE
cell line. Our previous results showed that the induced sputum from
COPD patients showed higher levels of ACh compared with smokers
and healthy control subjects [12]. In this study, we showed that ISSs
from COPD patients induced an increased production of ROS and that
Tiotropium is able to inhibit this effect in 16 HBE. These ﬁndings support
the presence and action of ACh in ISSs from COPD or a de novo ACh
synthesis during 16HBE stimulation. Based on the observations that
β2AR-agonists can have an antiinﬂammatory activity in primary lung
epithelial cells [29], we identiﬁed the antioxidant effect of Olodaterol
on ROS production in 16-HBE stimulated with ISS from COPD. In this
scenario, our ﬁndings support the concept that β2AR-agonists and
antimuscarinic drugs besides to maximize bronchodilatation in the
treatment of COPD, are able to reduce the oxidative/nitrosative stress
produced during airway inﬂammation from bronchial epithelial cells.
Finally, since β2 adrenoceptor agonist is able to mediate opposite effect
of muscarinic receptors, reducing endotelin-1 production in human
lung ﬁbroblasts [30] and is able to modulate inﬂammation in COPD
[20], accordingly our ﬁndings suggest that Olodaterol is able to control
ACh activity present or generated by ISS samples from COPD patients
reducing ROS production in 16-HBE.
Airway inﬂammatory cells especially eosinophils and epithelial cells
under inﬂammatory conditions, produce more superoxide anions (O2−)
and release reactive nitrogen compounds (NO) and reactive oxygen spe-
cies (ROS) than normal airway cells [1]. An excessive production of NO,
derived from the inducible type of NOS (iNOS, NOS2), reactswith super-
oxide anion O2− and produces peroxynitrite able to nitrate the tyrosine
residues of proteins to form the stable product of Nitrotyrosine [2], a
compound playing a pivotal role in the airway and lung parenchymal
Fig. 6.Hemicholinium (HCh-3) reduces the oxidative/nitrosative stress generated by ISSs from COPD patients in 16-HBE cells. The 16-HBE cells were stimulated for 30 min with ISSs
from COPD patients in the presence and absence of Hemicholinium (a potent choline uptake blocker). A) Western blot analyses were carried out sequentially with
anti-phosphoSTAT-1Ser727, anti-phosphoSTAT-1Tyr701, and anti-β-actin antibodies. Representative Western blot of phosphoSTAT-1Ser727, anti-phosphoSTAT-1Tyr701 and the
relative β-actin is shown. The bars represent the densitometric analysis of 3 separate experiments. At the end of the stimulation for 4 h B) ROS production was evaluated in the
cells by ﬂow cytometry, C) Nitrotyrosine in cell lysates by ELISA and D) iNOS expression by Western blot. Representative gel image of iNOS expression is shown. The results
were expressed as mean ± S.D. ANOVA with Fisher's test correction was used for the analysis of the data.
1956 M. Proﬁta et al. / Biochimica et Biophysica Acta 1832 (2013) 1949–1958inﬂammation [31–33]. A strong immunoreactivity to Nitrotyrosine
was observed in the epithelium, lung parenchyma, and inﬂammatory
cells (eosinophils, neutrophils) of patients with COPD [3]. Nitrotyrosine
and ROS production often coexists within the cells during airway in-
ﬂammation [4]. Accordingly, we showed that synthetic ACh and ISSs
from COPD patients are able to increase Nitrotyrosine production and
iNOS expression in cell extract of stimulated 16-HBE. In light of these
ﬁndings we suggest that synthetic ACh and mediators of inﬂammation
present in ISSs from COPD patients, are able to generate nitrosative
stress and iNOS expression. Finally, we showed that Tiotropium controls
the effect of synthetic ACh and that both Tiotropium and Olodaterol re-
duce the effect of ISSs onNitrotyrosine and iNOS expression in bronchial
epithelial cells. In this scenario, we suggest that β2-adrenoceptors are
able to oppose their activity to ACh present or de novo generated by
ISS samples from COPD patients during stimulation of 16HBE. However,
further molecular study will be necessary to better understand whether
Olodaterol directly inhibit cholinergic activity in bronchial epithelial
cells.
NF-κB pathway, mitogen-activated protein kinases (MAPK), and
Janus kinase (JAK)/STAT-dependent signaling pathways are involved
in iNOS expression in various cell types [7,34]. Particularly, uponactivation STATs become tyrosine phosphorylated, translocate to the
nucleus, and induce expression of target genes. Concurrently, Ser727
of STAT-1 is phosphorylated independently of tyrosine phosphorylation
and the full transcriptional activity of STAT-1 is also related to serine
phosphorylation [7]. One of the purposes of this study was to elucidate
the molecular mechanisms of ACh promotion of iNOS, emphasizing the
critical role of the key transcription factor STAT-1 on iNOS gene expres-
sion in 16-HBE cells. We found that the synthetic ACh and ISSs from
COPD promote the activation of STAT-1 Ser727 and Tyr701 phosphory-
lation suggesting that the increased expression of iNOS is related to
the downstream signaling activation involving the STAT-1 pathway.
However, the control value for the longer stimulation period with
ACh for iNOS and STAT-1 pathway activation is nearly identical to the
stimulated values in lower period stimulation groups, respectively.
Since these values are different from the other control value,we suggest
the involvement of low levels of autocrine production of ACh (time de-
pendent) in the regulation of iNOS/STAT-1 activity in cultured 16HBE.
Furthermore we observed that the antimuscarinic drug Tiotropium
controls the effect of ACh and both Tiotropium and β2AR-agonist
Olodaterol reduce the effect of ISSs on STAT-1 pathway activation.
These data conﬁrm that β2-adrenoceptors as the antimuscarinic drugs
Fig. 7. p91/STAT-1α silencing and oxidative/nitrosative stress in 16-HBE cells. A) Expression of p91/STAT-1α protein and iNOS in control cells and cells transfected with scrambled
siRNA or siRNA for p91/STAT-1α (a representative Western blot of p91/STAT-1α protein and iNOS is shown). The bars represent the densitometric analysis of 4 separate experi-
ments; B) expression of iNOS in control cells and cells transfected with siRNA for p91/STAT-1α stimulated with synthetic ACh and ISSs from COPD patients for 4 h was evaluated by
Western blot. A representative Western blot of iNOS and relative β-actin is shown. The bars represent the densitometric analysis of 6 separate experiments; C) intracellular ROS
production was evaluated by ﬂow cytometry; D) Nitrotyrosine levels were evaluated in cell extract by ELISA. The results were expressed as mean ± S.D. Statistical analysis was
performed by using ANOVA with Fisher's test correction.
1957M. Proﬁta et al. / Biochimica et Biophysica Acta 1832 (2013) 1949–1958are able to oppose their activity to ACh and to mediators of inﬂamma-
tion eventually present in ISSs. Finally, since HCh a potent uptake
choline blocker, added to the untreated or stimulatedwith ISS bronchial
epithelial cells, reduced the ROS, iNOs, Nitrotyrosine production and
STAT-1 pathway phosphorylation, we suggest the involvement of a de
novo ACh synthesis which generates the mechanism of oxidative/
nitrosative stress by STAT-1 downstream signaling activation in bron-
chial epithelial cells. These ﬁndings support the role of ACh in the
mechanism of airway inﬂammation during COPD.
However, the experiments of RNA interference of the STAT-1
pathway clarify the role of ACh in the iNOS expression, ROS and
Nitrotyrosine production obtained by STAT-1 pathway activation.
Furthermore, we observed that the pretreatment of 16-HBE with
Tiotropium and Olodaterol in combination additively reduced STAT-1
Ser727 and Tyr701 phosphorylation generated by ISSs from COPD,
which was not observed for ROS, Nitrotyrosine production and iNOS
expression. These ﬁndings suggest that antimuscarinic drugs and
β2AR-agonist might be able to reduce other inﬂammatory mechanism
generated by STAT-1 pathway activation. However further molecular
studies will be necessary to better understand the inhibition of STAT-1
pathway activation.
In conclusion, we demonstrated that the nonneuronal ACh present
in the airway of COPD might be cause of the degree of oxidative/
nitrosative stress generated by STAT-1 pathway activation in bronchial
epithelial cells. Furthermore, in this in vitro study we support thepotential therapeutic approach using antimuscarinics or long-acting
β2-agonists in patients with COPD to control the oxidative/nitrosative
stress generated in human bronchial epithelial cells by ACh. However,
further clinical study will be necessary to support the results and the
pharmacological approach described in our in vitro model of airway
inﬂammation.
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